All Cancer articles – Page 15
-
NewsKRAS variants in human pancreatic cancer: new key findings
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
-
News
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
-
Article
Looking beyond traditional oncogenic pathways to break cancer resistance
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional ...
-
NewsAnti-PD-1 autoantibody: a biomarker candidate for HCC
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
-
NewsLargest biobank of sarcoma-patient-derived organoids to date
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
-
ArticleInitial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy ...
-
News
RAD51C variants linked to increased breast and ovarian cancer risk
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
-
NewsBCL2 protein linked to metastatic castration-resistant prostate cancer
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
-
NewsNew network model efficiently identifies cancer driver genes
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
-
NewsNSD2’s role in driving prostate cancer development
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
-
NewsBrain organoids: investigating the progression of Huntington’s disease
Researchers found that HD can impair early brain development through defects associated with mitochondrial dysfunction.
-
NewsNovel compound for targeted alpha therapy
NpG-D-PSMA has shown great potential for targeted alpha therapy to combat prostate cancer.
-
NewsPancreatic cancer suppressed by humanised anti-CKAP4 antibody
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
-
ArticleAdvancing CAR-T therapy: how CD5 modulation is shaping cancer treatment
Vittoria Biotherapeutics is pioneering a novel form of CAR-T therapy for T-cell lymphoma using CRISPR gene editing. Here, co-founders Nicholas Siciliano and Marco Ruella explain how their approach promises to overcome tumour resistance, while also offering hope for new ways to treat solid cancers.
-
ArticleCombatting disease with antibody drug conjugates
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
-
NewsTransforming disease diagnosis with new nanoparticles
A new class of RNAs packed into extracellular vesicles have potential as biomarkers for prostate cancer and other diseases.
-
NewsKetogenic diet and a new cancer drug starves pancreatic cells
The discovery that eFT508 blocks eIF4E and the ketogenic pathway could provide the foundation for personalised therapies.
-
NewsLargest multi-omics study of colorectal cancer to date
Five distinct CRC prognostic subtypes were identified, which could revolutionise the way CRC is diagnosed and treated.
-
NewsGenetic variants influencing SR B-ALL relapse risk identified
Genome and transcriptome sequencing revealed that subtypes such as TCF3/4::HLF were associated with an increased risk of relapse.
-
NewsMelanoma: predicting immunotherapy-induced side effects
Increased gene activity in the SYK pathway could be the basis of a blood test to identify melanoma patients most susceptible to severe side effects.